Hypereosinophilic syndrome and mepolizumab [1]

New England Journal of Medicine

Volumn 358, Issue 26, 2008, Pages 2838-2840

  Verzegnassi, Federico ^a  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MEPOLIZUMAB; GLUCOCORTICOID; MONOCLONAL ANTIBODY; PREDNISONE;

DRUG DOSE TITRATION; DRUG EFFICACY; EOSINOPHIL COUNT; HYPEREOSINOPHILIC SYNDROME; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; DRUG COMBINATION; DRUG EFFECT; EOSINOPHIL; HUMAN; LEUKOCYTE COUNT; NOTE; DISEASE COURSE; TREATMENT FAILURE; TISSUE INJURY;

ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; EOSINOPHILS; GLUCOCORTICOIDS; HUMANS; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE COUNT; TREATMENT OUTCOME; DISEASE PROGRESSION; PREDNISONE; TREATMENT FAILURE;

EID: 45949097848     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc080856     Document Type: Letter

References (3)

1. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215-28.
2. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2007;2:37.
3. Ogbogu PU, Rosing DR, Horne MK III. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27:457-75.